Healthcare Services

Global Emphysema Industry Trends and Market Growth Forecast for 2026–2030

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Emphysema Market Projected To Become By 2030 Based On Its 2026 Valuation?

The emphysema market size has demonstrated consistent growth in recent years. It is projected to expand from $4.94 billion in 2025 to $5.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.6%. Historically, this growth can be attributed to factors such as smoking prevalence, air pollution exposure, an aging population, increased respiratory disease awareness, and the expansion of healthcare access.

The emphysema market is anticipated to experience consistent expansion in the coming years. This market is projected to reach $6.19 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.6%. The expansion during the forecast period can be attributed to early screening initiatives, the rise of home-based respiratory care, the adoption of advanced diagnostics, a stronger focus on chronic disease management, and environmental health regulations. Key trends shaping the forecast period involve the increasing prevalence of chronic respiratory diseases, an intensified focus on the early diagnosis of COPD, the growth in long-term oxygen therapy, the proliferation of pulmonary rehabilitation programs, and a significant emphasis on smoking cessation interventions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp

What Drivers Are Shaping The Future Growth Of The Emphysema Market?

The rising occurrence of respiratory infections is anticipated to boost the expansion of the emphysema market in the future. These infections target various parts of the respiratory system, such as the sinuses, throat, airways, and lungs. An increase in respiratory infections stems from factors like pollution, climate change, antimicrobial resistance, urbanization, and the emergence of new pathogens. They quicken the progression of emphysema by inducing inflammation, damaging tissues, and exacerbating airway obstruction, thereby deteriorating lung function. As an illustration, data from November 2024, provided by the Centers for Disease Control and Prevention, a US-based government agency, indicated that in 2023, the U.S. documented 9,633 tuberculosis (TB) cases, representing a 15.6% increase from the 8,332 cases recorded in 2022. This also saw the incidence rate climb by 15.0%, from 2.5 to 2.9 per 100,000 persons. Consequently, the rising incidence of respiratory infections is fueling the expansion of the emphysema market.

What Segment Groups Are Identified Within The Emphysema Market?

The emphysema market covered in this report is segmented –

1) By Type: Centrilobular, Panlobular

2) By Treatment: Medication, Therapy, Surgery, Other Treatments

3) By Diagnosis: Imaging Test, Lung Function Test, Other Diagnosis

4) By Complications: Chest Infections, Collapsed Lung, Heart Problems, Lungs Hole, Other Complications

5) By End-User: Hospitals And Clinics, Surgical Center, Other End-Users

Subsegments:

1) By Centrilobular: Mild Centrilobular Emphysema, Moderate Centrilobular Emphysema, Severe Centrilobular Emphysema

2) By Panlobular: Mild Panlobular Emphysema, Moderate Panlobular Emphysema, Severe Panlobular Emphysema

Which Market Trends Are Creating New Opportunities In The Emphysema Market?

Major companies operating in the emphysema market are actively pursuing medical innovations, such as advanced inhaled dual inhibitors of phosphodiesterase 3 and phosphodiesterase 4, to offer patients sophisticated treatments that can boost lung function, mitigate inflammation, and enhance the overall management of the condition, thereby promoting better respiratory health and an improved quality of life. An inhaled dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4 is a medication designed to target and block both phosphodiesterase enzymes within the lungs, which helps to relax the airways and decrease inflammation, leading to improved breathing in illnesses like chronic obstructive pulmonary disease. For instance, in June 2024, Verona Pharma plc, a UK-based pharmaceutical company, introduced Ohtuvayre (ensifentrine), which is the first inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a US-based federal agency, for the maintenance treatment of chronic obstructive pulmonary diseases such as emphysema, representing the first novel inhaled therapy in over two decades. This drug, which provides both bronchodilator and anti-inflammatory benefits, is slated to be made available through specialty pharmacies.

Which Companies Hold Significant Positions In The Emphysema Market?

Major companies operating in the emphysema market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann-La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, InMed Pharmaceuticals Inc.

Read the full emphysema market report here:

https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report

Which Geographic Regions Are Influencing Demand In The Emphysema Market?

North America was the largest region in the emphysema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Emphysema Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp

Browse Through More Reports Similar to the Global Emphysema Market 2026, By The Business Research Company

Anticoagulant Global Market Report

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Fluoxetine Global Market Report

https://www.thebusinessresearchcompany.com/report/fluoxetine-global-market-report

Isoflavones Global Market Report

https://www.thebusinessresearchcompany.com/report/isoflavones-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795